Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
NCT ID: NCT00121784
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
12 participants
INTERVENTIONAL
2005-10-31
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1
mycophenolate mofetil [CellCept]
1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mycophenolate mofetil [CellCept]
1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* receipt of first heart (single-organ) transplant;
* standard care regimen of CNI, MMF, and corticosteroids since transplantation.
Exclusion Criteria
* history of malignancies, other than non-melanoma skin cancer that has been totally excised with no recurrence for 2 years;
* patients participating in another interventional clinical trial or requiring treatment with unmarketed investigational drugs.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_CHAIR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chicago, Illinois, United States
Maywood, Illinois, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Charleston, South Carolina, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States
Darlinghurst, , Australia
Perth, , Australia
Prahran, , Australia
Innsbruck, , Austria
Marseille, , France
Nantes, , France
Paris, , France
Paris, , France
Rennes, , France
Rouen, , France
Tours, , France
Vandœuvre-lès-Nancy, , France
Berlin, , Germany
Hanover, , Germany
Heidelberg, , Germany
Jena, , Germany
Madrid, , Spain
Pamplona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT18328
Identifier Type: -
Identifier Source: org_study_id